{
    "eid": "2-s2.0-85100905088",
    "title": "Immune checkpoint inhibitor: An emerging treatment for head and neck cancer. a primer for the radiologist",
    "cover-date": "2020-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Radiology, Nuclear Medicine and Imaging",
            "@code": "2741",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "T. Sananmuang",
        "S. Prakkamakul",
        "N. Ngampaiboon",
        "S. H. Huang",
        "L. Alshafai",
        "E. Yu From"
    ],
    "citedby-count": 0,
    "ref-count": 127,
    "ref-list": [
        "Cancer statistics, 2020",
        "Epidemiology of head and neck cancer in Thailand",
        "Evidence for a causal association between human papillomavirus and a subset of head and neck cancers",
        "PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer",
        "Combined P16 and human papillomavirus testing predicts head and neck cancer survival",
        "Human papillomavirus as a diagnostic and prognostic tool in cancer of unknown primary in the head and neck region",
        "An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer",
        "Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer",
        "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)",
        "Cetuximab-containing combinations in locally advanced and recurrent or metastatic head and neck squamous cell carcinoma",
        "Platinum-based chemotherapy plus cetuximab in head and neck cancer",
        "Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining guidelines to assess the clinical benefit of cancer immunotherapy",
        "Nivolumab for recurrent squamous-cell carcinoma of the head and neck",
        "Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial",
        "Development of PD-1 and PD-L1 inhibitors as a formof cancer immunotherapy: A comprehensive review of registration trials and future considerations",
        "Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study",
        "Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study",
        "Clinical utility of the combined positive score for programmed death ligand- 1 expression and the approval of pembrolizumab for treatment of gastric cancer",
        "Anti-PD-1 and anti- CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations",
        "Cancer immunoediting and resistance to T cell-based immunotherapy",
        "The concept of immune surveillance against tumors. The first theories",
        "Patterns of response and progression to immunotherapy",
        "Imaging of tumour response to immunotherapy",
        "Immune checkpoint inhibitors: Recent progress and potential biomarkers",
        "Advances in cancer immunotherapy 2019 - latest trends",
        "The blockade of immune checkpoints in cancer immunotherapy",
        "Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation",
        "CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition",
        "The diverse functions of the PD1 inhibitory pathway",
        "Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPVassociated head and neck squamous cell carcinoma",
        "Immunotherapy for head and neck cancer: Where are we now and where are we going?",
        "Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: Clinical and immunological evidence from three patient cases",
        "Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression",
        "Cancer immunotherapy: Imaging assessment of novel treatment response patterns and immune-related adverse events",
        "Imaging of cancer immunotherapy: Current approaches and future directions",
        "Immune checkpoint inhibitor cancer therapy: Spectrum of imaging findings",
        "The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy",
        "Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria",
        "Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer",
        "Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma",
        "Hyperprogression under immunotherapy",
        "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada",
        "New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)",
        "Developing a common language for tumor response to immunotherapy: Immune-related response criteria using unidimensional measurements",
        "iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics",
        "Immune-related adverse events associated with immune checkpoint blockade",
        "Serious immunerelated adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review",
        "Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance",
        "Immune-related adverse events of immune checkpoint inhibitors: A brief review",
        "Tumour- and classspecific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review",
        "Immune checkpoint inhibitor toxicity in head and neck cancer: From identification to management",
        "Cancer immunotherapy-associated hypophysitis",
        "Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis",
        "Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy",
        "Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors",
        "Incidence rates of immunerelated adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO\u00feIPI: A systematic review and meta-analysis",
        "Severe inflammatory ophthalmopathy in a euthyroid patient during nivolumab treatment",
        "Immunotherapy in non-small cell lung cancer treatment: Current status and the role of imaging",
        "Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab",
        "Immunotherapy- induced endocrinopathies: Assessment, management and monitoring",
        "Endocrine toxicity of cancer immunotherapy targeting immune checkpoints",
        "Thyroid disorders induced by checkpoint inhibitors",
        "A case of Graves\u2019 ophthalmopathy associated with pembrolizumab (Keytruda) therapy",
        "Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients",
        "Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy",
        "Multimodality imaging of endocrine immune related adverse events: A primer for radiologists",
        "Rapid development of Graves\u2019 ophthalmopathy after treatment with ipilimumab and recurrence with pembrolizumab in a patient with previously treated graves\u2019 disease",
        "Endocrine side effects of cancer immunotherapy",
        "Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",
        "Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial",
        "Pembrolizumab versus ipilimumab in advanced melanoma",
        "Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma",
        "Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: Insights into pathogenesis from an autopsy series",
        "Combined nivolumab and ipilimumab or monotherapy in untreated melanoma",
        "Immunotherapy and hypophysitis: Clinical presentation, treatment, and biologic insights",
        "Immune check point inhibitors-induced hypophysitis: A retrospective analysis of the French Pharmacovigilance database",
        "Ipilimumab-induced hypophysitis: MR imaging findings",
        "Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature",
        "Neurological complications of immune checkpoint inhibitors: What happens when you\u2019take the brakes off\u2019 the immune system",
        "Neurologic complications of immune checkpoint inhibitors",
        "Neurologic immune-related adverse events associated with immune checkpoint inhibition",
        "Nivolumabinduced autoimmune encephalitis in two patients with lung adenocarcinoma",
        "Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: A single centre experience and review of the literature",
        "Neurologic complications of immune checkpoint inhibitors",
        "Neurological complications associated with anti-programmed death 1 (PD- 1) antibodies",
        "Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy-review of the literature and future outlook",
        "Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy",
        "Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis",
        "Limbic encephalitis following immunotherapy against metastatic malignant melanoma",
        "Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer",
        "Association of immune-mediated cerebellitis with immune checkpoint inhibitor therapy",
        "Subacute CNS demyelination after treatment with nivolumab for melanoma",
        "CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment",
        "Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma",
        "CTLA4 as immunological checkpoint in the development of multiple sclerosis",
        "Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade",
        "Pembrolizumab-induced CNS vasculitis",
        "Pembrolizumabrelated neuroinflammation: A case report and review of the literature",
        "Ipilimumabinduced encephalopathy with a reversible splenial lesion",
        "The price of tumor control: An analysis of rare side effects of anti- CTLA-4 therapy in metastatic melanoma from the ipilimumab network",
        "Fatal necrotizing encephalopathy after treatment with nivolumab for squamous non-small cell lung cancer: Case report and review of the literature",
        "Posterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non-small-cell lung cancer",
        "Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma",
        "Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma",
        "Neurologic immunerelated adverse events associated with adjuvant ipilimumab: Report of two cases",
        "Multiple cranial neuropathies from nivolumab in a patient with metastatic hepatocellular carcinoma",
        "Facial palsy induced by checkpoint blockade: A single center retrospective Study",
        "Granulomatous/ sarcoid-like reactions in the setting of programmed cell death-1 inhibition: A potential mimic of disease recurrence",
        "Granulomatous/ sarcoid-like lesions associated with checkpoint inhibitors: A marker of therapy response in a subset of melanoma patients",
        "Immune checkpoint inhibitor-induced sarcoidosis-like granulomas",
        "Neurosarcoidosis following immune checkpoint inhibition",
        "Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy",
        "Pembrolizumabinduced sarcoid-like reactions during treatment of metastatic melanoma",
        "Ocular adverse events with immune checkpoint inhibitors",
        "Checkpoint inhibitor immune therapy: Systemic indications and ophthalmic side effects",
        "PD-L1 testing in cancer: Challenges in companion diagnostic development",
        "Characteristics and impact of programmed death-ligand 1 expression, CD8\u00fe tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma",
        "The basis of oncoimmunology",
        "Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma",
        "A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: An imaging biomarker, retrospective multicohort study",
        "Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers",
        "Molecular imaging biomarkers for immune checkpoint inhibitor therapy",
        "Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: Introduction of iPERCIST",
        "Is it time to change our vision of tumor metabolism prior to immunotherapy?",
        "FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma",
        "89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199578",
            "affilname": "Ramathibodi Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199578",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Toronto",
            "@id": "60021600",
            "affilname": "University of Toronto Faculty of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021600",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "Toronto",
            "@id": "60016849",
            "affilname": "University of Toronto",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016849",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "Toronto",
            "@id": "60006894",
            "affilname": "Mount Sinai Hospital of University of Toronto",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006894",
            "affiliation-country": "Canada"
        }
    ],
    "funding": []
}